{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:12:46Z","timestamp":1792602766434,"version":"4.5.0"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T00:00:00Z","timestamp":1659657600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Hydroa vacciniforme-like lymphoproliferative disorder (HV-LPD) is a cutaneous form of chronic active Epstein-Barrvirus (EBV) infection, which can develop into the extremely rare systemic lymphoma. Patients with Inborn errors of immunity (IEI), such as common variable immunodeficiency (CVID), are at higher risk of developing a severe course of infections especially viral and malignancies than the general population. The aim of the study was to present complex diagnostic and therapeutic management of HV-LPD. The clinical diagnosis was confirmed at the histological and molecular level with next generation sequencing. HV-LPD was diagnosed in a patient with CVID and chronic active Epstein\u2013Barr virus (CAEBV) infection. The patient was refractory to CHOP chemotherapy and immunosuppressive treatment in combination with antiviral drugs (prednisone, bortezomib, gancyclovir). The third-party donor EBV-specific cytotoxic T cells (EBV-CTL, tabelecleucel) were used, which stabilised the disease course. Finally, matched unrelated donor hematopoietic cell transplantation (MUD-HCT) was performed followed by another cycle of EBV-CTL.<\/jats:p>","DOI":"10.3389\/fimmu.2022.915986","type":"journal-article","created":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T22:07:47Z","timestamp":1659737267000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["Case report: Cellular therapy for hydroa vacciniforme-like lymphoproliferative disorder in pediatric common variable immunodeficiency with chronic active Epstein-Barr virus infection"],"prefix":"10.3389","volume":"13","author":[{"given":"El\u017cbieta","family":"Grze\u015bk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylwia","family":"Ko\u0142tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"D\u0105browska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Urba\u0144czyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jadwiga","family":"Ma\u0142dyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogdan","family":"Ma\u0142kowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Bogiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"D\u0119bski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Czy\u017cewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariusz","family":"Wysocki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Styczy\u0144ski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.aller.2017.01.006","article-title":"Epidemiology and pathophysiology of malignancy in common variable immunodeficiency","volume":"45","author":"TakManesh","year":"2017","journal-title":"AllergolImmunopathol (Madr)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-381921","article-title":"EBV-associated T\/NK-celllymphoproliferativediseases in nonimmunocompromisedhosts: prospectiveanalysis of 108 cases","volume":"119","author":"Kimura","year":"2012","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/cup.12801","article-title":"Hydroa vacciniforme and hydroa vacciniforme-like T-cell lymphoma: an uncommon event for transformation","volume":"43","author":"Chen","year":"2016","journal-title":"J Cutan Pathol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-05-502203","article-title":"Hydroavacciniforme-likelymphoma: a chronic EBV+ lymphoproliferativedisorder with risk to develop a systemiclymphoma","volume":"122","author":"Quintanilla-Martinez","year":"2013","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-03-785931","article-title":"How I treat T-cell chronic active Epstein-Barr virus disease","volume":"131","author":"Bollard","year":"2018","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2021.798959","article-title":"Case report: Autoimmune lymphoproliferative syndrome vs. chronic active Epstein-Barr virus infection in children: A diagnostic challenge","volume":"9","author":"Szczawi\u0144ska-Pop\u0142onyk","year":"2021","journal-title":"Front Pediatr"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21239314","article-title":"Hydroa vacciniforme and hydroa vacciniforme-like lymphoproliferative disorder: A spectrum of disease phenotypes associated with ultraviolet irradiation and chronic Epstein-Barr virus infection","volume":"21","author":"Chen","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.20452\/pamw.4315","article-title":"The first polish cohort of adult patients with common variable immunodeficiency from 4 specialized centers: do we provide standards of care","volume":"128","author":"Wi\u0119sik-Szewczyk","year":"2018","journal-title":"Pol Arch Intern Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2018.00334","article-title":"Hematopoietic stem cell transplantation for the treatment of Epstein-Barr virus-associated T- or NK-cell lymphoproliferative diseases and associated disorders","volume":"6","author":"Sawada","year":"2018","journal-title":"Front Pediatr"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2018.00417","article-title":"Overview of EBV-associated T\/NK-cell lymphoproliferative diseases","volume":"6","author":"Kimura","year":"2019","journal-title":"Front Pediatr"},{"key":"B11","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1186\/s12889-020-09049-x","article-title":"Epidemiology of Epstein-Barr virus infection and infectious mononucleosis in the United Kingdom","volume":"20","author":"Kuri","year":"2020","journal-title":"BMC Public Health"},{"key":"B12","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1093\/ajcp\/aqw213","article-title":"T And NK-cell lymphomas and systemic lymphoproliferative disorders and the immunodeficiency setting: 2015 SH\/EAHP workshop report-part 4","volume":"147","author":"Gratzinger","year":"2017","journal-title":"Am J Clin Pathol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-04-842559","article-title":"Immunodeficiency-associated lymphoproliferative disorders: time for reappraisal","volume":"132","author":"Natkunam","year":"2018","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3960\/jslrt.19013","article-title":"Other iatrogenic immunodeficiency-associated lymphoproliferative disorders with a T- or NK-cell phenotype","volume":"59","author":"Satou","year":"2019","journal-title":"J Clin Exp Hematop"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2018893750","article-title":"Hydroavacciniforme-like lymphoproliferative disorder: an EBV disease with a low risk of systemic illness in whites","volume":"133","author":"Cohen","year":"2019","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-11-881268","article-title":"The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas","volume":"133","author":"Willemze","year":"2019","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13000-019-0859-4","article-title":"Clinicopathological categorization of hydroavacciniforme-like lymphoproliferative disorder: an analysis of prognostic implications and treatment based on 19 cases","volume":"14","author":"Guo","year":"2019","journal-title":"Diagn Pathol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1470.2010.01094.x","article-title":"Epstein-Barr Virus-associated hydroavacciniforme-like cutaneous lymphoma in seven Chinese children","volume":"27","author":"Xu","year":"2010","journal-title":"Pediatr Dermatol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/bjd.13411","article-title":"Survival rates and prognostic factors of Epstein-Barr virus-associated hydroavacciniforme and hypersensitivity to mosquito bites","volume":"172","author":"Miyake","year":"2015","journal-title":"Br J Dermatol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2010.176","article-title":"Long-term remission in a child with refractory EBV(+) hydroavacciniforme-like T-cell lymphoma through sequential matched EBV(+)-related allogeneic hematopoietic SCT followed by donor-derived EBV-specific cytotoxic T-lymphocyte immunotherapy","volume":"46","author":"El-Mallawany","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"B21","article-title":"Systemic lymphoma arising from hydroavacciniforme-like lymphoma: report of two cases with review of literature","volume":"7","author":"Yang","year":"2014","journal-title":"Int J Clin Exp Pathol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.01.011","article-title":"Hydroavacciniforme-like lymphoproliferative disorder: Clinicopathologic study of 41 cases","volume":"81","author":"Liu","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-12-756841","article-title":"PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK\/T-cell lymphoma failing l-asparaginase","volume":"129","author":"Kwong","year":"2017","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10153356","article-title":"Patients with common variable immunodeficiency complicated by autoimmune phenomena have lymphopenia and reduced treg, Th17, and NK cells","volume":"10","author":"Wi\u0119sik-Szewczyk","year":"2021","journal-title":"J Clin Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1007\/s00439-020-02145-3","article-title":"Genetic susceptibility to EBV infection: insights from inborn errors of immunity","volume":"139","author":"Tangye","year":"2020","journal-title":"Hum Genet"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3390\/cancers10060197","article-title":"Antiviral drugs for EBV","volume":"10","author":"Pagano","year":"2018","journal-title":"Cancers (Basel)"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.915986\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T22:07:51Z","timestamp":1659737271000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.915986\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,5]]},"references-count":26,"alternative-id":["10.3389\/fimmu.2022.915986"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.915986","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,5]]},"article-number":"915986"}}